Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05362760
Title Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA)
Recruitment Recruiting
Gender female
Phase FDA approved
Variant Requirements No
Sponsors Prof. W. Janni
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib + Exemestane

Abemaciclib + Fulvestrant

Abemaciclib + Letrozole

Abemaciclib + Anastrozole

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.